STOCK TITAN

Acelrx Pharmaceuticals Inc - ACRX STOCK NEWS

Welcome to our dedicated news page for Acelrx Pharmaceuticals (Ticker: ACRX), a resource for investors and traders seeking the latest updates and insights on Acelrx Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Acelrx Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Acelrx Pharmaceuticals's position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.14%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.29%
Tags
partnership
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.46%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.46%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.54%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.76%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.83%
Tags
conferences
Acelrx Pharmaceuticals Inc

Nasdaq:ACRX

ACRX Rankings

ACRX Stock Data

14.58M
12.03M
2.64%
38.89%
3%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Redwood City

About ACRX

acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v